This is a Validated Antibody Database (VAD) review about human LGMN, based on 5 published articles (read how Labome selects the articles), using LGMN antibody in all methods. It is aimed to help Labome visitors find the most suited LGMN antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
LGMN synonym: AEP; LGMN1; PRSC1; legumain; asparaginyl endopeptidase; cysteine protease 1; protease, cysteine 1; protease, cysteine, 1 (legumain)

Knockout validation
R&D Systems
goat polyclonal
  • western blot knockout validation; human; loading ...; fig 2a
R&D Systems LGMN antibody (R&D System, AF2199) was used in western blot knockout validation on human samples (fig 2a). Onco Targets Ther (2017) ncbi
R&D Systems
goat polyclonal
  • western blot knockout validation; human; loading ...; fig 2a
R&D Systems LGMN antibody (R&D System, AF2199) was used in western blot knockout validation on human samples (fig 2a). Onco Targets Ther (2017) ncbi
goat polyclonal
  • immunohistochemistry - paraffin section; human
  • western blot; human
In order to determine the subcellular expression and proteolytic activity patterns of legumain in tumor tissue, R&D Systems LGMN antibody (R&D, AF2199) was used in immunohistochemistry - paraffin section on human samples and in western blot on human samples . Eur J Cancer (2015) ncbi
goat polyclonal
  • immunocytochemistry; human; 1:50
  • western blot; human; 1:1000
R&D Systems LGMN antibody (R&D Systems, AF2199) was used in immunocytochemistry on human samples at 1:50 and in western blot on human samples at 1:1000. PLoS ONE (2014) ncbi
goat polyclonal
  • immunohistochemistry - paraffin section; human; 1:300
  • immunocytochemistry; human; 1:100
  • western blot; human; 1:1000
R&D Systems LGMN antibody (R&D Systems, AF2199) was used in immunohistochemistry - paraffin section on human samples at 1:300, in immunocytochemistry on human samples at 1:100 and in western blot on human samples at 1:1000. PLoS ONE (2013) ncbi
Santa Cruz Biotechnology
mouse monoclonal (B-8)
  • immunohistochemistry - paraffin section; human; 1:400; loading ...; fig 6d
  • western blot; human; loading ...; fig 6b
In order to propose that altered legumain activity in the bone microenvironment results in decreased bone mass in postmenopausal osteoporosis, Santa Cruz Biotechnology LGMN antibody (Santa Cruz, SC-133234) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig 6d) and in western blot on human samples (fig 6b). Stem Cell Reports (2017) ncbi
Articles Reviewed
  1. Cui Y, Li Q, Li H, Wang Y, Wang H, Chen W, et al. Asparaginyl endopeptidase improves the resistance of microtubule-targeting drugs in gastric cancer through IQGAP1 modulating the EGFR/JNK/ERK signaling pathway. Onco Targets Ther. 2017;10:627-643 pubmed publisher
  2. Jafari A, Qanie D, Andersen T, Zhang Y, Chen L, Postert B, et al. Legumain Regulates Differentiation Fate of Human Bone Marrow Stromal Cells and Is Altered in Postmenopausal Osteoporosis. Stem Cell Reports. 2017;8:373-386 pubmed publisher
  3. Haugen M, Boye K, Nesland J, Pettersen S, Egeland E, Tamhane T, et al. High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting. Eur J Cancer. 2015;51:9-17 pubmed publisher
  4. Smith R, Solberg R, Jacobsen L, Voreland A, Rustan A, Thoresen G, et al. Simvastatin inhibits glucose metabolism and legumain activity in human myotubes. PLoS ONE. 2014;9:e85721 pubmed publisher
  5. Haugen M, Johansen H, Pettersen S, Solberg R, Brix K, Flatmark K, et al. Nuclear legumain activity in colorectal cancer. PLoS ONE. 2013;8:e52980 pubmed publisher